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Comparative proteomic profiling 
reveals mechanisms for early spinal 
cord vulnerability in CLN1 disease
Hemanth R. Nelvagal1,5, Maica Llavero Hurtado6, Samantha L. Eaton6, Rachel A. Kline6, 
Douglas J. Lamont7, Mark S. Sands2,4, Thomas M. Wishart6 & Jonathan D. Cooper1,2,3,5*
CLN1 disease is a fatal inherited neurodegenerative lysosomal storage disease of early childhood, 
caused by mutations in the CLN1 gene, which encodes the enzyme Palmitoyl protein thioesterase-1 
(PPT-1). We recently found significant spinal pathology in Ppt1-deficient (Ppt1−/−) mice and human 
CLN1 disease that contributes to clinical outcome and precedes the onset of brain pathology. Here, 
we quantified this spinal pathology at 3 and 7 months of age revealing significant and progressive 
glial activation and vulnerability of spinal interneurons. Tandem mass tagged proteomic analysis of 
the spinal cord of Ppt1−/−and control mice at these timepoints revealed a significant neuroimmune 
response and changes in mitochondrial function, cell-signalling pathways and developmental 
processes. Comparing proteomic changes in the spinal cord and cortex at 3 months revealed many 
similarly affected processes, except the inflammatory response. These proteomic and pathological 
data from this largely unexplored region of the CNS may help explain the limited success of previous 
brain-directed therapies. These data also fundamentally change our understanding of the progressive, 
site-specific nature of CLN1 disease pathogenesis, and highlight the importance of the neuroimmune 
response. This should greatly impact our approach to the timing and targeting of future therapeutic 
trials for this and similar disorders.
The neuronal ceroid lipofuscinoses (NCLs) are a group of fatal inherited neurodegenerative lysosomal storage 
disorders affecting children and young  adults1,2. CLN1 disease or infantile NCL is a rapidly progressing form 
caused by mutations in the CLN1 gene, which encodes a lysosomal de-palmitoylating enzyme, Palmitoyl Protein 
Thioesterase-1 (PPT-1)3,4. Despite the recent development an FDA-approved disease-limiting therapy for CLN2 
disease, there no curative therapy for CLN1  disease5.
This lack of therapeutic efficacy may be due to other disease loci not targeted by brain-directed  therapies6–8. 
We recently demonstrated the existence of significant pathology in the spinal cords of human CLN1 patients at 
autopsy and in Ppt1-deficient (Ppt1−/−)  mice9. The onset of spinal pathology in Ppt1−/− mice preceded similar 
changes in the brain, and therapeutically targeting the spinal cord of Ppt1−/− mice either alone or in combination 
with the brain, significantly ameliorated pathology and improved  lifespan9. However, the exact nature and extent 
of spinal pathology, particularly before the brain is affected is yet to be defined, and the mechanisms underlying 
such regional vulnerability are yet to be elucidated.
In this study, we characterized pathological changes in the spinal cords of Ppt1−/− mice at 3 months, the time-
point when we first saw significant neuron loss, and at disease end-stage at 7  months9. This revealed significant 
changes in spinal cord volume, glial activation and interneuron survival at 3 months of age. We then used com-
parative proteomic profiling strategies to help elucidate the underlying mechanisms of this regional pathology. 
Our findings indicate the alteration of distinct cell-signalling pathways, developmental processes, mitochondrial 
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dysfunction and most notably, a significant neuroinflammatory response in the spinal cords of Ppt1−/− mice at 
3 months of age that is not observed in their cortex at the same age. Together, these data highlight the significant 
and early extent of disease in the CLN1 disease spinal cord, identifying vulnerable spinal cell populations and 
region-specific disease mechanisms that may underlie spinal cord vulnerability in this disease.
Results
Early and progressive pathological changes in Ppt1−/− spinal cord. Stereological estimates of Nissl-
stained sections of 3 and 7 month old wildtype and Ppt1−/− mouse spinal  cords10,11 revealed significantly lower 
total volume, grey matter and white matter volumes at 3 months of age in Ppt1−/− mice, which worsened by 
7 months of age (Fig. 1A). In marked contrast, the brains of these mice show little white matter pathology any 
stage of disease progression, and no significant regional atrophy until 5 months of  age10. Analyzing the cervical 
and lumbo-sacral regions of the Ppt1−/− cord separately revealed similar changes at both levels, with only cervical 
white matter in Ppt1−/− mice at 3 months of age not showing significantly reduced volume. This is indicative of 
little rostro-caudal difference in these volumetric changes in the Ppt1−/− spinal cord (Supplementary Figure S1).
We have previously qualitatively described dramatic increases in astrocytosis and microglial activation in the 
grey matter of cervical and lumbar spinal cords of Ppt1−/−  mice9. Quantifying similarly stained sections for GFAP 
(astrocytes) and CD68 (microglia), showed a significant and progressive increase in both markers from 3 months 
of age that equally affected the dorsal and ventral horns, and occurred both in the cervical and lumbo-sacral 
regions (Fig. 1B, Supplementary Figure S1). The similar effects within dorsal and ventral horns suggest that these 
glial changes are not confined to either sensory or motor pathways, unlike the regional specificity observed in 
the brain and  cerebellum12,13. We previously showed significant loss of Nissl-stained neurons as early as 3 months 
of age in the cervical and lumbar spinal cords of Ppt1−/−  mice9 that occurs before any neuron loss in the  brain12. 
To further characterize the nature of neuron loss in the spinal cord, we analyzed sections stained for interneu-
ron markers (calbindin, calretinin) and motor neurons (CD-71), which represent major neuronal populations 
in the spinal grey  matter14,15. This unbiased stereological analysis revealed a significant loss of interneurons 
in both the cervical and lumbo-sacral cords of Ppt1−/− mice at 3 months of age, whereas motor neurons were 
only significantly decreased at 7 months of age (Fig. 1C; Supplementary Figure S1). Therefore, the Nissl stained 
neuron loss seen in these  mice9 is likely due to interneuron loss rather than loss of motor neurons. Importantly, 
these interneuron populations are potentially more vulnerable to CLN1 disease and show a progressive decline 
in number between 3 and 7 months, as they do in the  brain12.
Figure 1.  Early and progressive spinal cord pathology in Ppt1−/− mice. Stereological analysis of regional volume 
(A) in the spinal cord reveals significant reduction in total, grey and white matter in whole Ppt1−/− cords at 3 and 
7 months of age compared to wildtype (WT) controls. Thresholding imaging analysis (B) of sections stained for 
microglia (CD68) and astrocytes (GFAP) show a significant increase in both markers in the dorsal and ventral 
horns of the lumbo-sacral cord at early (3MO) and late (7MO) disease states in Ppt1−/− cords compared to 
WT. Counts of neuron number in the lumbo-sacral cord (C) revealed a significant loss of Ppt1−/− mouse spinal 
interneurons stained with calbindin and calretinin in laminae IV-IX as early as 3 months of age, compared to 
WT. However, spinal motor neurons in the ventral horns (CD-71) were only significantly lost at 7 months of 
age in Ppt1−/− mouse spinal cords. Scale bars 200 µm. p values—**p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001; multiple 
two-tailed, unpaired, parametric t test with Bonferroni–Dunn correction. Values shown are mean ± SEM. (n = 5 
mice/group).
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Together, these data establish the spinal cord as a particularly vulnerable region of the CNS in CLN1 disease, 
with significant pathological changes evident earlier than the brain regions we have previously  characterized11–13. 
The loss of interneurons before motor neurons is indicative of these being vulnerable neuronal populations, as 
seen in the  forebrain12. However, the lack of rostro-caudal differences or differences between the dorsal and 
ventral horns, shows there to be a more widespread and less regionally selective pathology in the spinal cord.
Quantitative proteomic profiling of whole tissue lysates spinal cord and cortex at early and 
late stages (3 and 7 months). To further characterize the changes occurring in the spinal cord in CLN1  
disease, we processed whole wildtype and Ppt1−/− cortical and spinal cord extracts using Tandem mass tag-
ging (TMT) based quantitative  proteomics16,17. We analyzed 6 groups in detail- 3 month cortices and spinal 
cords as well as 7 month spinal cords from WT and Ppt1−/− mice respectively (Fig. 2A, https ://doi.org/10.7488/
ds/2750 (2020)). The 7,970 protein raw data outputs from LC–MS were filtered to include proteins with ≥ 2 pep-
tides identified, considered more reliable  observations18. These proteins were then cross-referenced with mouse 
(Mus musculus) protein sequences from UniProtKB/Swiss-Prot using the MASCOT search engine (Matrix Sci-
ence, Version 2.2) through Proteome Discoverer (Version 1.4, ThermoFisher) for a total of 7,160 identified pro-
teins (https ://doi.org/10.7488/ds/2750 (2020)) (Fig. 2B). We then used the PANTHER gene ontology  database19 
(Fig.  2C) and the Database for Annotation, Visualization and Integrated Discovery (DAVID)20,21 to confirm 
that the list of proteins identified was representative of whole tissue lysates and not enriched in any particular 
sub-cellular compartment (Supplementary David Ontology File). LC–MS data for markers shown to be altered 
from spinal cord immunohistochemistry (Fig. 1) were identified showing an increase in CD68 ratios. However, 
GFAP was not greatly increased in the 3-month-old spinal cord ratios, presumably due to its high expression in 
the white matter of the cord, even in WT tissue, but this increased at 7 months, and was also increased in the 
cortex at 3 months. There was little change in the expression of interneuron markers calbindin and calretinin, 
Figure 2.  Experimental design workflow and sample validation. Schematic (A) diagram representing the 
various stages of experimental workflow for LC–MS/MS and in silico analysis of proteomic data set. (B) 
Schematic depicting the filtration of raw LC–MS data by first identifying those with ≥ 2 peptides, cross-
references with Proteome Discoverer. These were then filtered using a 1.2-fold cut off for Ppt1−/−/WT ratios 
for each individual comparison or without a cut-off by using BioLayout Express 3D clustering. The numbers 
of resulting proteins used for each comparison are referenced below. Filtered proteins were then input for IPA 
analysis. Pie chart diagram (C) of the main biological function/subcellular compartments identified by Panther 
enrichment analysis showing a lack of any particular enrichment of proteins.
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possibly due to the relatively low abundance of cells expressing these markers (Supplementary Table S1). We 
also validated these data using quantitative fluorescent western blotting (QFWB) of representative proteins from 
samples used for LC–MS (Supplementary Figure S2). Representative proteins that showed increased, decreased 
or relatively unaltered Ppt1−/−/WT abundance ratios, together with markers relevant to CLN1 disease pathology 
were chosen to appropriately validate the LC–MS data, including markers for synaptic  proteins22, astrocytes, 
 interneurons11,12 and for oligodendrocytes (MBP). Overall our QFWB analysis showed similar trends to the 
predicted LC–MS data (Supplementary Table). SNAP25 which was significantly downregulated in the spinal 
cord as compared to the cortex, and synaptophysin showed little change across all groups. Little overall change 
in protein abundance was also observed in QFWB data for calbindin and cytochrome oxidase subunit IV (COX 
IV), consistent with LC–MS data (Supplementary Figure S2). These synaptic markers, calbindin and COX IV 
all showed an overall increased abundance in the cortex as compared to the spinal cord, as is expected given the 
higher density of cells expressing these markers in the  cortex15,23. We also probed astrocyte markers—GFAP was 
significantly up regulated in the cortex at 3 months and spinal cord at 7 months, with only a trend to increased 
values at 3 months in the spinal cord, while glutamine synthetase did not show any significant change across 
groups, again consistent with the LC–MS data (Supplementary Figure S2). Lastly, Myelin basic protein (MBP) 
was more abundant in the spinal cord as compared to the cortex, which contains less white matter, but was 
decreased in 3 and 7 month Ppt1−/− cords (Supplementary Figure S2). Functional proteomic analysis was car-
ried out by filtering for proteins with increased stringency- either including those proteins with 1.2 fold (20%) 
expression change in Ppt1−/− tissues, compared to  wildtype18,24 or by BioLayout Express 3D to cluster proteins 
that show similar changes in  expression16–18,25–28 (Fig. 2B). These data were then analyzed using the ingenuity 
pathway analysis (IPA) (Ingenuity systems) software to reveal the cellular pathways that may be altered in these 
different  regions16,18,26–28.
Significant neuroimmune and inflammatory responses in Ppt1−/− spinal cords at 3 months of age. The expres-
sion ratios (Ppt1−/−/WT) from spinal cord comparisons at 3 months identified a total of 7,160 proteins and were 
evaluated using IPA software, which mapped the majority of the proteins to the Ingenuity Knowledge database 
(7,096). We applied 1.2-fold (20%) expression change (Ppt1−/−/WT) as a cut-off, which yielded 249 (117 up- 
and 132 downregulated) (Fig. 2B) differentially expressed proteins. IPA analysis of affected cellular (canonical) 
pathways showed significant changes in the inflammatory pathways in the 3 month Ppt1−/− spinal cord. The 
top canonical pathways affected included phagosome maturation (p = 7.98E−07) and autophagy (p = 5.37E−06) 
(Fig.  3, Supplementary Table  S2), which are anticipated given the intrinsic link between lysosomal function 
and  autophagy29–31 and the significant microglial activation observed by immunohistochemistry (Fig. 1). Fur-
thermore, interferon signalling (p = 4.48E−05), antigen presentation (p = 5.86E−05) and T-lymphocyte mediated 
apoptosis (p = 4.08E−04) were also affected indicative of a pronounced humoral immune system involvement at 
this earlier time point (Fig. 3).
IPA software was utilized to determine which cellular networks are most affected by interrogating curated 
list of known networks of protein interactions. This analysis further highlighted the significant inflammatory 
response, as the most enriched networks involved—Humoral Immune Response, Inflammatory Response and 
Nutritional Disease (Fig. 3, Supplementary Table S2, IPA-Score = 52, 28 focus molecules). The next most enriched 
networks were Cell Morphology, Cellular Assembly and Organization (IPA-Score = 42, 24 focus molecules) 
(Fig. 3, Supplementary Table S3) and Cell-To-Cell Signalling and Interaction, Nervous System Development, 
Cell Morphology (IPA-Score = 35, 21 focus molecules). The top predicted upstream regulators also included a 
predicted activation of interferon gamma (p = 8.37E−12, activation z-score (z) = 4.11) and Interferon alpha/beta 
receptor (IfNAR, p = 6.51E−14, z = 3.831), which are linked with a humoral immune response. There was also 
a predicted activation of STAT1 (p = 2.25E−06, z = 3.795), interferon regulatory factor 7 (IRF7, p = 8.85E−10, 
z = 2.837) and inhibition of TRIM 24 (p = 3.33E−13, z = − 3.819). These predicted regulatory alterations emphasize 
the findings of affected canonical pathways and highlight the extent of inflammatory changes in the Ppt1−/− spinal 
cord at 3 months of age. Using the IPA analysis to further dissect which pathological disease processes are most 
affected, we found expected changes in lysosomal proteins (p = 8.98E−12, z = − 2.193), with other NCL proteins 
being upregulated as previously  described32,33 (Fig. 4). Other disease-associated processes included accumulation 
of lipid (p = 1.38E4, z = − 3.229), immune response of cells and quantity of CD8 positive cells (p = 4.3E5, z = 3.252), 
glial morphology (p = 1.21E−09, z = − 0.68), neurodegenerative changes (p = 8.03E5, z = 0.813), movement disor-
ders (p = 5.93E6, z = − 1.664), abnormal myelination (p = 8.71E−10, z = 0.898) and sensory system development 
(p = 7.39E4, z = 0.83) (Fig. 4, Supplementary Table S4).
Overall, analyzing proteins whose expression changed by 1.2-fold or more at 3 months in Ppt1−/− spinal cord 
revealed significant inflammatory changes, particularly a large humoral immune response. While the effect of 
infiltrating lymphocytes on the Ppt1−/− mouse brain has been well  documented34,35, this only occurred much 
later in disease progression.
To validate this proteomic finding of comparatively early spinal peripheral lymphocyte infiltration, we immu-
nostained WT and Ppt1−/− spinal cords sections at 3 and 7 months simultaneously for peripheral lympho-
cyte markers CD4 and  CD835. This staining showed positive lymphocytes in in the grey and white matter of 
Ppt1−/− spinal cords, even at the early 3 month timepoint (Supplementary Figure S1), confirming the changes 
seen in the proteomic analysis. This is significantly earlier than similar changes are observed in the brains of 
these  mice35. Furthermore, proteomic analysis revealed protein changes associated with abnormal myelination, 
which we confirmed by QFWB analysis of MBP (Supplementary Figure S2), as well as other pathophysiological 
mechanisms including nervous system development and movement disorders that have not been previously 
described for this disease. These serve to not only demonstrate the relatively early onset of pathology in this 
region of the CNS, but may also help understand the cause of such vulnerability.
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Early vs. late changes in the Ppt1−/− spinal cord. We next analyzed Ppt1−/− vs. wildtype spinal cords at 7 months, 
using the 1.2-fold cut-off as above. This yielded 1,441 (924 up- and 217 downregulated) (Fig.  2B) differen-
tially expressed proteins (compared to 249 at 3  months), indicative of the progressive worsening phenotype 
of CLN1 disease in the spinal cord. This analysis revealed that the major canonical pathways and cellular net-
works affected at disease end-stage differ from those identified at the early symptomatic stage at 3  months, 
including Integrin signalling (p = 3.80E−11), cholesterol biosynthesis (p = 3.21E−10), Rho GTPase signalling 
(p = 2.83E−07), ILK Signaling (p = 3.66 E−07) and opioid signalling pathways (p = 4.67E−07) (Supplementary 
Figure S3, Supplementary Table S10). In order to compare affected pathways between 3 and 7 month timepoints, 
we used IPA software to generate a comparative heatmap of altered canonical pathways revealing many more 
affected pathways with disease progression (Fig. 5A). While this might be expected, several processes including 
interferon signalling (3 month z = 2.236, 7 month z = 1.0), Production of Nitric Oxide and Reactive Oxygen Spe-
cies in Macrophages (3 month z = 2.0, 7 month z = 0.78), Protein Kinase A signalling (3 month z = 0.81-, 7 month 
z = − 1.22) and TEC Kinase signalling (3 month z = 1.63, 7 month SC z = 0.94) were all unexpectedly more pro-
nounced at 3 months of age. These data indicate that there is not simply a worsening of common phenotypes 
with progressing disease, but rather that there are certain pathological processes that are more florid at early 
symptomatic stages in the Ppt1−/− cord, and whose involvement decreases with age.
Studying those proteins whose expression ratio changed by 1.2-fold (20%) or more highlights the most 
significant pathological changes at each time point. However, to dissect which of these processes are distinct 
or common between 3 and 7 months in Ppt1−/− cords, we also analyzed these datasets using BioLayout Express 
3D16–18,25–28. We input the expression ratios (Ppt1−/−/WT) of 7,160 proteins from LC–MS without a filtering cut-
off for 3 and 7 month-old spinal cords (Fig. 2B). Individual protein clusters were grouped based on trends of 
expression as those that showed more changes at (a) 3 months (2,096 proteins); (b) 7 months (3,159 proteins); 
or (c) clusters that showed progressive or similar changes between timepoints (1,541 proteins) (Fig. 5B). IPA 
software was then used for a functional cellular pathway analysis of each group.
Figure 3.  Early proteomic changes in the spinal cord of Ppt1−/− mice. Analysis of the differentially expressed 
proteins in the spinal cord of Ppt1−/− mice at 3 months of age. Proteins that were differentially expressed by 1.2 
fold (20%) were linked using Ingenuity Pathway Analysis (IPA). The top affected canonical pathways (A) and two 
of the most significantly affected networks (B)—humoral immune response (IPA Score = 52, 28 focus molecules) 
and cell morphology, function and maintenance (IPA Score = 42, 24 focus molecules) are shown here. (See 
Supplementary Tables S2, S3 and Supplementary Excel File for further details.)
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IPA analysis of changes of BioLayout Express 3D clusters predominant at the 3 month timepoint, revealed a 
surprising enrichment of proteins associated with mitochondrial dysfunction (p = 5.46E−15), involving com-
plexes I, III, IV and V (Fig. 6A, Supplementary Table S5), protein ubiquitination (p = 6.31E−11), oxidative 
phosphorylation (p = 1.25E−10), EIF2 signaling (p = 2.23E−09) and tRNA charging (p = 1.42E−07). We then 
looked at which cellular functions and diseases were enriched within this dataset—revealing a predicted increase 
in organismal death (p = 1.11E−12, z = 3.644) and mortality (p = 3.98E−12, z = 3.565), dysfunction of neurons, 
(p = 4.29E−05, z = 2.164), benign lesions (p = 0.000307, z = 2.0) and a decrease in development of cytoplasm 
(p = 2.81E−12, z = − 3.095) and cytoskeleton (p = 2.03E−09, z = − 2.85), formation of filaments (p = 2.03E−09, 
z = − 2.85), potentiation of the synapse (p = 5.01E−08, z = − 2.521) and microtubule dynamics (p = 1.95E−14, 
z = − 2.124) (Supplementary Figure S4A, Supplementary Table S11). There were also changes involving develop-
ment of the CNS (p = 1.23E−6, z = − 2.035) and development of the synapse (p = 3.63E−08, z = 0.451).
Further dividing the BioLayout 3D clusters predominantly altered in the 3 month Ppt1−/− spinal cord into 
those proteins that showed increased (993 proteins) or decreased expression (1,103 proteins) revealed that while 
mitochondrial dysfunction and oxidative phosphorylation changes were the main canonical pathways associated 
with increased expression in the 3 month Ppt1−/− spinal cord in these protein clusters (p = 8.43E−24, 3.39E−18, 
respectively) (Fig. 6B, Supplementary Table S6), the main pathways associated with decreased expression were 
EIF2 signalling, eIF4 and p70S6K regulation, Protein Kinase A Signalling, Polo-Like Kinase and mTOR signal-
ling (p = 1.35E−10, 1.55E−06, 8.60E−06, 1.68E−05, 9.06E−05, respectively) (Fig. 6C, Supplementary Table S6). 
These findings are of particular importance as they highlight early and distinct disease-related changes in the 
CLN1 spinal cord that decrease with age. These changes are possibly indicative of either altered postnatal matu-
ration  processes32, and/or increased cell turnover due to cell loss in the 3 month old Ppt1−/− spinal cord (Fig. 1).
Similarly, IPA analysis of BioLayout 3D clusters with progressive or similar changes at 3 and 7 months showed 
RAC signalling, Axonal guidance, Rho family GTPase signalling, Stathmin1 regulation of breast cancer and ARP-
WASP complex1 to be significantly altered (p = 7.09E−10, 1.19E−09, 2.91E−09, 3.84E−08, 1.03E−07, respectively) 
(Supplementary Figure S4B, Supplementary Table S11). Interestingly, these clusters were primarily comprised of 
Figure 4.  Early disease and/or cellular function changes in the spinal cord of Ppt1−/− mice. Analysis of 
the differentially expressed proteins by 1.2 fold (20%) in the spinal cord of Ppt1−/− mice at 3 months of age, 
linked using Ingenuity Pathway Analysis (IPA). Various processes affected included—lysosomal protein 
defects (p = 8.98E−12, z = − 2.193), accumulation of lipid (p = 1.38E4, z = − 3.229), immune response of 
cells and quantity of CD8 positive cells (p = 4.3E5, z = 3.252), glial morphology (p = 1.21E−09, z = − 0.68), 
neurodegenerative changes (p = 8.03E5, z = 0.813), movement disorders (p = 5.93E6, z = − 1.664), abnormal 
myelination (p = 8.71E−10, z = 0.898) and sensory system development (p = 7.39E4, z = 0.83). (Further details 
available including larger versions of images available in Supplementary Information, Supplementary Table S4 
and Supplementary Excel File).
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proteins that were downregulated. IPA analysis of protein clusters that show changes at 7 months of age (late in 
the disease) showed that the integrin signalling, Rho family GTPase signalling, FAK signalling, Rho GDI signal-
ling and insulin receptor signalling were significantly altered (p = 1.87E−17, 4.00E−12 31.0, 1.26E−11, 1.91E−11, 
2.00E−11 respectively) (Supplementary Figure S4C, Supplementary Table S12).
Together, our comparative proteomic analyses reveal multiple pathological processes occurring in the 
Ppt1−/− mouse spinal cord at 3 months, highlighting its significant involvement relatively early in disease. Inter-
estingly, dissecting up- and down-regulated processes revealed the involvement of distinct early disease-related 
changes including mitochondrial dysfunction, cancer pathways, mTOR signalling and developmental processes. 
While these have previously been shown to be linked to PPT1 function in vitro33,36, and our data confirms this 
alteration in vivo for the first time at a significantly earlier timepoint than previously predicted. Early involve-
ment of these cellular processes that play a role in spinal cord development and/or function may further help 
explain spinal cord vulnerability in CLN1 disease.
Figure 5.  Early vs. late proteomic changes in the spinal cord of Ppt1−/− mice. (A) Comparative proteomic 
profiling of differentially expressed proteins by 1.2 fold (20%) in the spinal cord of Ppt1−/− mice at 3 (early) and 
7 (late) months of age respectively revealed an overall increase in the number and degree of change in the later 
timepoints. However, some pathways were more affected at 3 months of age including interferon signalling 
(3 month SC z = 2.236–3 month SC, 7 month SC z = 1.0), Production of Nitric Oxide and Reactive Oxygen 
Species in Macrophages (3 month SC z = 2.0-, 7 month SC z = 0.78-), Protein Kinase A signalling (3 month 
SC z = 0.81, 7 month SC z = − 1.22) and TEC Kinase signalling (3 month SC z = 1.63, 7 month SC z = 0.94). (B) 
BioLayout Express 3D clustering representation of proteomic expression data for 3- and 7-month-old Ppt1−/− 
spinal cords, and a normalised WT group. Each sphere or node represents a single protein, and edges or lines 
represent the relatedness of proteins to one another, in this case, based on similarity in expression profile. 
Applying the Markov Clustering Algorithm in BioLayout Express 3D clusters these nodes based on similarity in 
expression profile. As a result, proteins exhibiting similar expression trends to one another are not only grouped 
closely in spatial proximity within the graph but also are coloured identically to represent membership within 
the same cluster. The expression profile behind each cluster can then be individually analysed to identify and 
isolate those that show more change at 3 months of age, 7 months of age or those that show a similar/progressive 
change.
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Comparing Ppt1−/− cortical and spinal cord changes highlights conserved and divergent mechanisms. Although 
significant pathology is already underway in their spinal cord at 3 months, the cortex of Ppt1−/− mice shows 
no significant glial activation, accumulation of storage material or neuron loss at this  timepoint11,12. Therefore, 
having elucidated various altered cellular processes associated with spinal cord pathology, we compared the pro-
teomic changes that occur in the spinal cord at 3 months with changes seen in the cortex at this age. Despite the 
obvious cytoarchitectural and biochemical differences between these tissues, such a comparison would reveal 
common and distinct mechanisms responsible for regional CLN1 disease progression.
We first filtered proteins from the cortex at 3 months that showed a 1.2-fold (20%) change in Ppt1−/− tissue. 
This yielded 705 proteins (343 up- and 362 downregulated) (compared to 249 proteins with a similar change 
in the 3 month cord) (Fig. 2B). While this may be due to greater coverage of cortical proteins with LC–MS and 
IPA analysis, there was a significant overlap of affected cellular processes between the cortex and spinal cord. 
Top affected canonical pathways included LXR/RXR Activation, autophagy, mitochondrial dysfunction, oxida-
tive phosphorylation and phagosome maturation (p = 1.04E−06, 2.78E−06, 6.33E−06, 6.87E−06 and 1.46E−05, 
respectively) (Supplementary Figure S5, Supplementary Table S13). Similarly, the cellular networks most affected 
included Cell Morphology, Cellular Assembly and Organization, Carbohydrate Metabolism (IPA-score = 52), 
Metabolic Disease, Cellular Compromise, Embryonic Development (IPA-score = 42), Energy Production, Molec-
ular Transport, Nucleic Acid Metabolism (IPA-score = 39), Cardiovascular System Development and Function, 
Embryonic Development, Organ Development (IPA-score = 39) and Cellular Development, Post-Translational 
Modification, Hair and Skin Development (IPA-score = 39) (Supplementary Figure S5, Supplementary Table S14). 
These data highlight the great similarity in the most affected pathways in the cortex and spinal cord, with the 
cortex showing a higher expression fold change. The degree of change in cortical protein expression was particu-
larly striking as there is little histologically detectable pathology observed at this stage in this brain  region11,12. 
However, a marked exception to this broad similarity between regions was the degree of altered inflamma-
tory pathways, especially the humoral immune response pathways, revealing a potential cause for spinal cord 
Figure 6.  Biolayout express 3D clustering analysis of changes in the spinal cord of Ppt1−/− mice at 3 months 
of age. Top affected canonical pathways from the analysis of (A) the differentially expressed protein clusters 
that showed increased and decreased expression at 3-month-old Ppt1−/− cords, compared to normalized WT 
and 7-month-old cord. Mitochondrial dysfunction, the top affected pathway is highlighted to show affected 
proteins (red/green). IPA analysis of only those protein clusters showing increased expression (B) or decreased 
expression (C) at 3-month-old Ppt1−/− spinal cords, compared to normalized WT and 7-month-old spinal cord 
revealed differentially affected canonical pathways. (See Supplementary Tables S5, S6, S7 and Supplementary 
Excel File for further details.)
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vulnerability. This was further highlighted when we compared affected canonical pathways between 3 month 
cortices and spinal cords (Fig. 7A), where affected pathways including interferon signalling (z = 2.236-SC, 2.0-
Ctx), Production of nitric oxide and reactive oxygen species in macrophages (z = 2.0-SC, 1.5-Ctx), pattern rec-
ognition receptors for bacteria and viruses (z = 1.89-SC, 0.7-Ctx), Tec Kinase signalling (z = 1.63-SC, 1.41-Ctx), 
GP6 Signalling Pathway (z = 1-SC, 0-Ctx) and complement system (z = 1-SC,0-Ctx) were all more affected in the 
cord than in the cortex of Ppt1−/− mice at 3 months.
Using BioLayoutExpress 3D16–18,25–28, we inputted expression ratios (Ppt1−/−/WT) of 7,160 proteins without 
a cut-off for the cortex and spinal cord at 3 months respectively (Fig. 2B). We then clustered proteins based 
on whether these changes occurred more in the spinal cord (2,341 Proteins), cortex (2,371 Proteins) or both 
regions (1,179 Proteins). Analysis of clusters most impacted in the cortex revealed affected canonical path-
ways included caveolar-mediated endocytosis signalling, Integrin signalling, mTOR signalling, regulation of eIF4 
and p70S6K signalling and EIF 2 signalling (p = 1.24E−1, 8.89E−11, 7.14E−10, 8.27E−10, 3.24E−09, respectively) 
(Fig. 7B, Supplementary Table S8). Many of these processes were also shown to be altered in the 3 month spinal 
cord, but to a lesser extent, highlighting the common pathological processes between these regions. Analyzing 
protein clusters that showed more changes in the spinal cord revealed affected canonical pathways-Dopamine-
DARPP32 Feedback in cAMP Signaling (p = 7.91E−10), Breast Cancer Regulation by Stathmin1 (p = 2.06E−08), 
CREB Signaling in Neurons (p = 2.35E−08), CDK5 Signaling (p = 5.26E−08), GNRH Signaling (p = 9.36E−08), 
indicating that these cell signaling pathways may be uniquely dysregulated in the spinal cord (Fig. 7C, Supple-
mentary Table S10).We then analyzed clusters for similar protein expression changes between the spinal cord and 
cortex, revealing common pathways—Synaptic Long Term Potentiation (p = 6.10E−07), G Beta Gamma Signal-
ing (p = 1.05E−06), Opioid signaling Pathway (p = 6.19E−06), CREB Signaling in Neurons (p = 1.11E−05) and 
adrenergic Signaling (p = 2.46E−05), further highlighting the synaptic defects observed early in disease in these 
 mice34,35, also revealing novel cell-signalling pathways (Supplementary Figure S6, Supplementary Table S15).
Figure 7.  Cortical vs. spinal cord proteomic changes in 3-month-old Ppt1−/− mice. (A) Analysis of the 
differentially expressed proteins by 1.2 fold (20%) in the spinal cord and cortex of Ppt1−/− mice revealed 
a greater number of affected pathways in the cortex, with some pathways more affected in the spinal cord 
including—interferon signalling (z = 2.236-SC, 2.0-Ctx), Production of nitric oxide and reactive oxygen species 
in macrophages (z = 2.0-SC, 1.5-Ctx), pattern recognition receptors for bacteria and viruses (z = 1.89-SC, 0.7-
Ctx), Tec Kinase signalling (z = 1.63-SC, 1.41-Ctx), GP6 Signalling Pathway (z = 1 SC, 0-Ctx) and complement 
system (z = 1-SC,0-Ctx). BioLayout Express 3D clustering analysis of the expression trends between 3-month-
old Ppt1−/− mouse cortex, spinal cord and normalized WT control (see methods) revealed the top affected 
canonical pathways in the cortex (B) and spinal cord (C), respectively. (See Supplementary Tables S8, S9 and 
Supplementary Excel File for further details.)
10
Vol:.(1234567890)
Scientific RepoRtS |        (2020) 10:15157  | https://doi.org/10.1038/s41598-020-72075-7
www.nature.com/scientificreports/
Overall, these analyses show similarities in the cellular pathways impacted by disease in the cortex and spi-
nal cord of Ppt1−/− mice. Despite a lesser extent of histopathological phenotypes, the cortex showed a greater 
degree of change in terms of protein expression in these shared pathways as compared to the spinal cord. We 
cannot discount the differences in cytoarchitecture or cellular function between the cortex and spinal cord as 
influencing these data. Nevertheless, the extent of overlap of changes seen between the cortex and spinal cords 
of Ppt1−/− mice demonstrate the significance of cellular processes that precede neurodegeneration. However, the 
most conspicuous difference we detected was the degree of inflammatory changes, particularly humoral immune 
response in the Ppt1−/− spinal cord as compared to the cortex at this relatively early stage of disease, in addition 
to revealing the presence of unique cell signalling pathways within the spinal cord.
Discussion
CLN1 disease is a rapidly progressing form of NCL with no curative therapy  available1,5. Despite the success of 
enzyme replacement therapy for CLN2  disease37, brain-directed therapies have not been as effective for CLN1 
 disease1,5. We recently showed significant spinal pathology in CLN1 disease patients and Ppt1−/− mice, which 
contributes to disease outcome and unexpectedly precedes the onset of brain  pathology9. Therefore, in this study, 
we firstly characterized the nature and progression of CLN1 disease in the spinal cords in more detail, showing 
significant early changes in regional volume, glial activation and interneuron number in these mice at 3 months of 
age. We then elucidated disease mechanisms that may explain the regional differences in the CNS of Ppt1−/− mice.
Histopathological analysis of Ppt1−/− mouse spinal cords at 3 and 7 months of age revealed progressive changes 
in regional volume that affect both the grey and white matter, a significant activation of astrocytes and microglia, 
and a selective loss of interneuron populations before motor neurons. This spinal pathology affected both dorsal 
and ventral horns and also affected different levels of the spinal cord to a similar extent.
The mouse spinal cord is fully developed by 3  months38. However, as the Ppt1−/− spinal cord is already smaller 
in volume at this age, it raises the possibility that the spinal cord may not have developed normally. Whether 
this is due to defects in embryonic development or post-natal maturation is yet to be determined and may help 
explain this regional vulnerability.
The activation of microglia and astrocytes is a more accurate predictor of neuron loss in the NCLs than the 
accumulation of storage  material12,39. Given the inherent defects of Ppt1−/− mouse cortical astrocytes and micro-
glia in vitro and their impact on neuron  survival40, as well as the importance of neuroinflammatory changes in 
other neurodegenerative  pathologies41,42, our data provide evidence for a distinct pathogenic role of glial acti-
vation in regional vulnerability in CLN1 disease. However, this awaits further experimental validation in vivo 
and it will be important to characterize the inflammatory networks involved in the early pathogenesis of CLN1 
disease. To achieve this goal a comprehensive analysis of early cytokine and chemokine changes, in addition to 
defining the activation states of astrocytes and microglia and the role they play in regional neurodegeneration 
is currently ongoing.
The Ppt1−/− mouse brain shows also selective neuron loss, with interneurons and large complex neurons 
such as lamina V cortical neurons and cerebellar Purkinje cells particularly  vulnerable12,13. While Ppt1−/− mouse 
spinal cords show significant overall neuron loss at 3  months9, our data now show spinal interneurons are lost 
significantly before motor neurons in the Ppt1−/− spinal cord. To date this is the earliest significant cell loss seen in 
these mice, highlighting the severity of spinal pathology and revealing a different pattern of cellular vulnerability 
to other  NCLs43 and to diseases such as amyotrophic lateral sclerosis (ALS) and other motor neuron diseases 
(MNDs)44–47. Therefore, it will be critical to study the precise relationship between glial activation and neuron 
loss in the CLN1 disease spinal cord, and investigations into neuron-glial interactions in this especially vulnerable 
region of the CNS are currently ongoing. Together, our histopathological characterization has emphasized the 
extent and significant progression of spinal pathology in the cord of Ppt1−/− mice, that precedes brain pathology 
and has identified spinal interneurons and glia as being particularly involved early in this disease.
We next undertook a comparative proteomic investigation of Ppt1−/− and wildtype mouse spinal cords to 
investigate the mechanisms driving spinal cord vulnerability in CLN1 disease. Our comparison of proteins 
altered in 3 month old cords revealed significant alterations in autophagy, phagocytosis and neuroinflamma-
tory processes. In particular, there was a profound humoral immune response in the Ppt1−/− spinal cord which 
is progressive until 7 months. The status of the blood brain barrier (BBB) has previously been detailed in CLN1 
 disease35,48, with CD4 and CD8 + ve lymphocytes, seen infiltrating the Ppt1−/− mouse optic nerve and brain as 
early as 3  months35. Taking into account our proteomic findings, we validated these findings by immunostain-
ing 3 and 7 month spinal cord sections at the same time for both CD4 and CD8 + ve lymphocytes. This revealed 
increased infiltration of these cells at 3 months of age, significantly earlier than similar changes occur in the brains 
of these  mice35. Unlike the BBB, the blood-spinal cord-barrier (BSCB) is relatively more porous and therefore 
potentially more vulnerable to lymphocyte  infiltration49–51. However, the BSCB has yet to be studied in any form 
of NCL, and our data suggest performing a detailed investigation. Interestingly, the expression of PPT1 is most 
abundant in CD8 + ve dendritic cells and microglia in mice, with comparable expression in humans (www.biogp 
s.org (2020))52. Therefore, as we have documented inherent defects in microglia and  astrocytes40, peripheral blood 
lymphocytes may be also vulnerable to CLN1 disease and require further characterization.
We also demonstrated alterations in a variety of cellular processes including mitochondrial dysfunction, oxi-
dative phosphorylation and TCA Cycle function, EIF2, EIF4 and p70SK, mTOR pathway. These alterations have 
previously been described in CLN1 disease either in vitro in neuroblastoma  cells33 and cancer cell  lines36 or in a 
CLN1 mouse model that bears a different disease-causing mutation (Ppt1△ex4)32. Our data confirm these shared 
pathological processes also occur in the more commonly used Ppt1−/− mice, and that these pathological changes 
are ongoing at this relatively early time point in the spinal cord. Despite having specific disease-causing mutations 
and the unique pathomechanisms discussed here, the Ppt1−/− mouse cortex and spinal cord also show alterations 
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in biological processes that are significantly affected in a host of neurodegenerative  conditions53–56. Such common 
pathogenic mechanisms may prove critical in understanding the downstream cellular consequences of lysosomal 
pathology and may also prove to be amenable to therapeutic intervention. Given the regional vulnerability of 
the spinal cord, cell populations within the cord may be more vulnerable to alterations in these processes than 
other cell types, however, this awaits experimental confirmation.
Given marked differences in the onset of histologically detectable pathology in the spinal cord and cortex of 
Ppt1−/−  mice9,12, proteomic profiling revealed surprisingly similar changes in protein expression in these two CNS 
regions at 3 months of age. Despite the cortex being relatively spared in terms of glial activation and neuron loss 
at 3 months, there were many similar processes altered in this brain region as in the spinal cord and many of these 
were to a greater extent than in the cord. While this may be in part due to inherent differences in cellular and 
biochemical constitution, these data reiterate the similarity in disease processes across the CNS regions and shift 
the focus upon regional and cell-type vulnerability to these alterations. However, the most conspicuous difference 
between the Ppt1−/− mouse cortex and spinal cord at 3 months was the remarkable extent of immune response 
present in the cord at this early stage of disease, and work into characterizing the exact nature and progression 
of these changes in currently ongoing. As already discussed, whether this is due to inherent cell-type defects 
or as a reaction to regional cues is yet to be determined, but these data help us understand the cause of such 
regional differences in vulnerability. Furthermore, our data raise the possibility of spinal cord targeted regional 
therapeutic interventions such as anti-inflammatories or neuroprotective  agents57,58 to improve disease outcome.
Taken together, this study provides a thorough characterization of early symptomatic spinal cord pathology in 
CLN1 disease, and using comparative proteomic profiling, elucidates significantly affected cellular mechanisms 
that contribute to this early regional vulnerability. In particular, we highlight spinal interneurons and glial cells 
as the earliest observed vulnerable cell populations. Early alterations in cell-signalling, developmental processes, 
mitochondrial dysfunction and a significant spinal cord immune response may play a major role in disease 
progression and regional vulnerability in Ppt1−/− mice. It is now apparent that CLN1 disease does not just affect 
the brain. Characterizing and subsequently targeting the early inflammatory response observed in Ppt1−/− spinal 
cords may therefore prove to be an effective strategy either alone or in combination with other therapies, as has 
become increasingly common across the  NCLs57,59,60. Such characterization of the pathomechanisms of CLN1 
disease and other forms of NCLs can directly inform therapeutic efforts in order to significantly improve disease 
outcomes.
Methods
Animals. The Ppt1−/− mouse was created by targeted gene disruption that eliminates the last exon of the Ppt1/
Cln1  gene61. These mice were backcrossed with C57BL/6 mice for more than 10 generations and maintained as 
a homozygous breeding stock. Ppt1−/− and age-matched C57BL/6 control mice were bred and housed in a bar-
rier facility at the Institute of Psychiatry, Psychology and Neuroscience, King’s College London (London, UK). 
All procedures were approved by the Denmark Hill Animal Welfare and Ethics Body and carried out under the 
Animals (Scientific) Procedures Act, 1986 (UK) (Project Licences 70/6567 and 70/7364).
Immunohistochemistry. Histological tissue processing. Mice at 3 and 7 months of age were anesthetized 
with sodium pentobarbitone (100  mg/kg) and perfused transcardially with heparinised PBS followed by 4% 
formaldehyde in PBS, pH 7.4. Whole mice were post-fixed in this 4% formaldehyde solution for a further 48 h 
before being transferred to a 50 mM Tris solution (TBS). Spinal cords were separated from the brainstem from 
the dorsal aspect, just below the foramen magnum. The entire spinal column was then dissected out from the 
surrounding tissue, and the spinal cord was dissected from the column by initial dorsal laminectomy followed by 
separation and removal of individual vertebrae. The spinal cords were cryoprotected in 30% sucrose in 50 mM 
TBS, pH 7.6. 40 µm coronal sections were then cut on a Microm HM430 freezing microtome (Microm Interna-
tional GmbH, Wallendorf, Germany).
Cresyl fast violet staining (Nissl staining). Cresyl fast violet staining was performed by mounting a one in 24 
series of sections on to chrome-gelatin coated slides and leaving them to air-dry overnight at room temperature. 
The slides were then incubated in 0.1% cresyl fast violet solution with 0.05% acetic acid (VWR) overnight, before 
being differentiated by passing through a graded series of Industrial Methylated Spirit (IMS) solutions (70%, 
80%, 90% and 2 × 100%), before being cleared in Xylene (VWR) and coverslipped in DPX (VWR).
Immunohistochemical staining. A one in 24 series of spinal cord sections from each animal were immu-
nostained free-floating for markers of astrocytosis (rabbit anti-GFAP, 1:8,000 dilution, Dako Ltd); microglial 
activation (rat anti-mouse CD68, 1:2,000 dilution, AbD Serotec); interneurons (rabbit anti-Calbindin, 1:10,000 
dilution, Swant; rabbit anti-Calretinin, 1:5,000 dilution, Swant), motor neurons (rat anti-CD71, 1:200 dilution, 
AbD Serotec); and peripheral lymphocyte markers (rat anti-CD4, 1:50 dilution, AbD Serotec, Rat anti-CD8, 
1:100 dilution, AbD Serotec). Endogenous peroxidase activity in the sections was quenched with 1%  H2O2 in 
TBS with 0.3% Triton-X100 (TBS-T), washed and then blocked in 15% normal serum (Vector Laboratories) 
diluted in TBS-T. The species of normal serum was directed against the host species of the secondary antibody. 
After blocking, sections were incubated overnight at 4 °C in primary antibody diluted in 10% normal serum 
in TBS-T. Sections were then washed and incubated at room temperature in biotinylated secondary antibody 
at 1:1,000 dilution (biotinylated swine anti-rabbit IgG, DAKO; biotinylated rabbit anti-rat IgG, Vector Labora-
tories), followed by washing and incubation in Vectastain Elite ABC kit (1:1,000, Vector Laboratories) before 
visualization with 3,3′-diaminobenzidine tetrahydrochloride (DAB) (Sigma). Sections were then mounted on to 
chrome-gelatin coated slides, air-dried overnight, cleared in xylene (VWR) and coverslipped in DPX.
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Measurement of regional volume. Regional volumes were measured as previously  described10, where whole 
spinal cord volumes and spinal cord grey matter volumes were measured in a one in 24 series of sections for each 
spinal cord. Using the Cavalieri estimator, estimates of volume in cubic µm were obtained by superimposing a 
125 μm grid on Nissl-stained sections and using Stereo Investigator software (Microbrightfield Inc, Williston, 
Vermont) linked to a Zeiss Axioskop 2 MOT (Zeiss, Germany) with a DAGE-MTI CCD-100 camera (Dage-
MTI, Michigan City, Iowa). White matter volumes were obtained as a subtractive value of the whole volume and 
grey matter volume of each spinal cord section, with reference to a spinal cord  atlas15.
Thresholding image analysis. To analyze glial activation in the grey matter of sections stained for GFAP and 
CD68, as well as neuron density in Laminae I-III of sections stained for interneuron markers, we performed 
thresholding image analysis using Image Pro Premier software (Media Cybernetics, Chicago, IL, USA). Here, 
30 non-overlapping images from 3 sections at 40× magnification for the glial markers and 50 non-overlapping 
images from 5 sections at 63× magnification for interneuron markers, were captured for each defined region, 
with all parameters of light intensity, camera setup and calibrations being kept constant. An appropriate thresh-
old was applied to each set of images so as to select the positive foreground immunoreactivity over the back-
ground. Results were obtained as an average percentage area of positive staining per  image62.
Interneuron and motor neuron counts. Due to the relatively low numbers of interneurons, stereological meth-
ods prove inefficient for counting  them63. Counts for neurons in Laminae IV–X in a one in 24 series of sections 
immunostained for interneuron markers (Calbindin, Calretinin) and motor neuron markers (CD-71), was car-
ried out manually using unbiased sampling. Each section was visualized at 10× magnification using a Axioplan 
microscope (Zeiss) and a live video camera (Luminera Infinity 3URM Colour camera), with Image Pro Premier 
software (Media Cybernetics, Chicago, IL, USA). Total estimates were obtained as the product of the counted 
cells, periodicity and the number of intervals.
Proteomic processing. Protein extraction for liquid chromatography-with tandem mass tagged-mass spec-
trometry (LC–MS/MS). Mice at 3 and 7 months of age were euthanized in a  CO2 chamber, followed by isolation 
of the spinal column with scissors at the base of skull and at the pelvic bone. The skull was then dissected to 
remove the brain and the cortices were isolated. A 20 ml syringe with TBS and an 18G needle was then inserted 
into the rostral end of the vertebral column, ensuring a tight fit. The spinal cord was then extruded by hydraulic 
pressure into a glass petri dish containing TBS as previously  described64. Collected cortices and spinal cords were 
then frozen at − 80 °C prior to proteomic analysis.
Sample preparation for Tandem–Mass–Tag proteomic analysis was carried out as previously  described16,17. 
Briefly, samples were homogenized in extraction buffer [100 mM Tris–HCl (pH7.6) 4% (w/v) SDS] containing 
1% protease cocktail inhibitor (Thermo Fisher, UK). Post homogenization, samples were spun at 300×g for 2 min 
and left on ice for 20 min. Homogenates were transferred to Lo-Bind 1.5 ml tubes (Sigma Aldrich) and centri-
fuged at 20,000×g for 20 min at 4 °C with the soluble fraction of each sample then transferred to new Lo-Bind 
tubes. Protein determination using the bicinchoninic acid assay (BCA) (Pierce, UK) was carried out according to 
manufacturer’s guidelines. Samples were then pooled into groups for a single tissue region at a single timepoint 
per genotype (n = 4 or 5 mice) as follows – 3 month wild type (WT) cortex, 3 month Ppt1−/− cortex, 3 month WT 
spinal cord, 3 month Ppt1−/− spinal cord, 7 month WT cortex, 7 month Ppt1−/− cortex, 7 month WT spinal cord 
and 7 month Ppt1−/− spinal cord (https ://doi.org/10.7488/ds/2750 (2020)). Individual samples containing 20 μg 
of protein per sample within each group, i.e., equivalent amounts of protein from all samples—were pooled to 
generate a condition specific master sample of 100 μg protein.
TMT proteomic analysis of the pooled samples was performed by the FingerPrints Proteomics facilities at 
the University of Dundee. Pooling according to sample type allows a reduction in potential noise in the system 
generated through inter individual differences, subtle post-mortem handling differences and/or sample isolation. 
The inclusion of an equivalent proportion of each individual sample into a readily comparable pool allows the 
generation of a molecular fingerprint representative of each condition and enables subsequent analysis of indi-
vidual patient variability in the resulting validatory work (as a deviation from the population signal, as previously 
 described17,18,65,66). Indeed, we have previously demonstrated that pooling can enable the reliable identification 
of up to 3× more proteins in complex  samples26.
Sample processing was carried out as follows: protein samples were thawed, trypsinized and desalted at room 
temperature. 100 μg of desalted tryptic peptides per sample were dissolved in 100 μl of 100 mM tetraethylam-
monium bromide (TEAB). The 8 different tandem mass tag (TMT) labels comprising the TMT8plex kit (Thermo 
Fisher Scientific) were dissolved in 41 μl anhydrous acetonitrile. Each dissolved label was added to a different 
sample—3 month WT cortex (Tag 127N), 3 month Ppt1−/− cortex (Tag 127C), 3 month WT spinal cord (Tag 
129N), 3 month Ppt1−/− spinal cord (Tag 129C), 7 month WT cortex (Tag 128N), 7 month Ppt1−/− cortex (Tag 
128C), 7 month WT spinal cord (Tag 130N )and 7 month Ppt1−/− spinal cord (130C) (https ://doi.org/10.7488/
ds/2750 (2020)). The sample-label mixture was incubated for 1 h at room temperature. Labelling reaction was 
stopped by adding 8 μl of 5% hydroxylamine per pooled sample.
As  per16,17, following labelling with TMT, pooled samples were desalted, and dried in a speed-vac at 30 °C, 
re-dissolved in 200 μl ammonium formate (10 mM, pH 10) and peptides were fractionated using an Ultimate 
3,000 High Performance Liquid Chromatography column (Thermo-Scientific) containing an XBridge C18 col-
umn (XBridge peptide BEH, 130 Å, 3.5 μm, 2.1 × 150 mm) (Waters, Ireland) with an XBridge guard column 
(XBridge, C18, 3.5 μm, 2.1 × 10mm) (Waters, Ireland). Buffers A (10 mM ammonium formate in milliQ water) 
and B (10 mM ammonium formate with 90% acetonitrile) were adjusted to pH 10 with ammonia. Fractions were 
collected using a WPS-3000FC auto-sampler (Thermo-Scientific) at 1 min intervals. Column and guard column 
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were equilibrated for 20 min at a constant flow rate of 0.2 ml/min. 175 μl per sample was loaded onto the column 
at a rate of 0.2 ml/min, and the separation gradient was started 1 min after sample was loaded onto the column. 
Peptides were eluted from the column with a gradient of 2–5% Buffer B in 6 min, and then from 5 to 60% Buffer 
B in 50 min. The column was washed for 16 min in Buffer B and re-equilibrated at 2%. The fraction collection 
started 1 min after injection and stopped after 80 min (total 80 fractions, 200 μl each). The total number of frac-
tions concatenated was set to 15 and the content of the fractions was dried and suspended in 50 μl of 1% formic 
acid prior to analysis with LC–MS/MS.
LC–MS/MS analysis. Liquid chromatography–tandem mass spectrometry was performed by FingerPrints Pro-
teomics Facilities at the University of Dundee, as  per16,17. Briefly, analysis of peptide readout was performed on 
a Q Exactive HF Hybrid Quadrupole-Orbitrap Mass Spectrometer (Thermo Scientific) coupled with a Dionex 
Ultimate 3000 RS (Thermo Scientific). LC buffers were made up to the following: Buffer A [2% acetonitrile and 
0.1% formic acid in Milli-Q water (v/v)] and Buffer B (80% acetonitrile and 0.08% formic acid in Milli-Q water 
(v/v). Aliquots of 15 μl per sample were loaded at a rate of 5 μl/min onto a trap column (100 μm × 2 cm, PepMap 
nanoViper C18 column, 5 μm, 100 Å, Thermo Scientific) which was equilibrated with 98% Buffer A. The trap 
column was washed for 6 min at the same flow rate and then the trap column was switched in-line with a resolv-
ing C18 column (Thermo Scientific) (75 μm × 50 cm, PepMap RSLC C18 column, 2 μm, 100 Å). Peptides were 
eluted from the column at a constant flow rate of 300 nl/min with a linear gradient from 95% Buffer A to 40% 
Buffer B in 122 min, and then to 98% Buffer B by 132 min. The resolving column was then washed with 95% 
Buffer B for 15 min and re-equilibrated in 98% Buffer A for 32 min. Q Exactive HF was used in data dependent 
mode. A scan cycle was comprised of a MS1 scan (m/z range from 335 to 1,800, with a maximum ion injec-
tion time of 50 ms, a resolution of 120,000 and automatic gain control (AGC) value of 3 × 106) followed by 15 
sequential-dependent MS2 scans (with an isolation window set to 0.4 Da, resolution at 60,000, maximum ion 
injection time at 200 ms and AGC 1 × 105. To ensure mass accuracy, the mass spectrometer was calibrated on the 
first day that the runs were performed.
Protein identification. Raw MS data were searched against mouse (Mus musculus) protein sequences from Uni-
ProtKB/Swiss-Prot using the MASCOT search engine (Matrix Science, Version 2.2) through Proteome Discoverer 
software (Version 1.4, Thermo Fisher). Parameters for database search were as follows: MS1 Tolerance: 10 ppm; 
MS2 Tolerance: 0.06da; fixed modification: Carbamidomethyl (C) Variable Modification: Oxidation (M), Dioxi-
dation (M), Acetyl (N-term), Gln- > pyro-Glu (N-term Q), TMT 10(N-term and K); maximum missed cleavage: 
2; and target FDR 0.01. All identifications were quantified as relative ratios of expression of Ppt1−/− to wildtype 
tissue at each time point for each tissue. Of these, six groups—3 month WT cortex, 3 month Ppt1−/− cortex, 
3 month WT spinal cord, 3 month Ppt1−/− spinal cord, 7 month WT spinal cord and 7 month Ppt1−/− spinal cord 
were taken forward for further analysis. Relative abundance ratios along with UnitProtKB/Swiss-Prot identifica-
tions were exported into Microsoft Excel as a raw data file containing ID, ratio of change in expression at each 
time point (Data available here: https ://doi.org/10.7488/ds/2750 (2020)).
Quantitative fluorescent western blotting (QFWB). QFWB was also done as previously  described18,67. Briefly, 
samples were denatured in NuPage LDS Sample buffer 4X (Invitrogen, UK) at 98 °C and 10ug of protein loaded 
and run on 4–20% TGX Stain-free gels (Bio-Rad, Hercules, CA). Accuracy of loading and protein estimation was 
confirmed by total protein analysis of TGX stain-free gels after exposure to UV light in a ChemiDoc Imager as 
per manufacturer’s instructions (Bio-Rad) . Protein transfer to a polyvinylidene fluoride (PDVF) membrane was 
carried out using the TransBlot Turbo system using manufacturer recommended transfer packs (Bio-Rad). Mem-
branes were incubated with Odyssey blocking buffer (Li-Cor) for 1 h. Next, membranes were incubated in pri-
mary antibodies (Rabbit anti-SNAP25, 1:4,000 , Abcam; Rat anti-myelin basic protein (MBP), 1:500, EMD Mil-
lipore (18–20 kD band analyzed as per manufacturer’s product data sheet); Rabbit anti-COXIV, 1:2000, Abcam; 
Mouse anti-glial fibrillary acidic protein (GFAP), 1:2000, Sigma-Aldrich; Rabbit anti-calbindin, 1:2000,Swant; 
Mouse anti-synaptophysin, 1:8,000, Enzo Life sciences and Mouse anti-glutamine synthetase, 1:4,000, BD Bio-
sciences) overnight at 4 °C and secondary antibodies (goat anti-rabbit 680 nm, 1:4,000, goat anti-rat 800 nm and 
goat anti-mouse 800 nm, RD) for 2 h at room temperature. Visualization and analysis was carried out with the 
ChemiDoc Imager and Image Lab software (Bio-Rad). Quantification was performed on single channels with the 
analysis software provided.
Biolayout express 3D. Unfiltered lists comprised of protein IDs with corresponding expression ratios at each 
time point relative to the equivalent timepoint wildtype value (available here: https ://doi.org/10.7488/ds/2750 
(2020)) were imported separately into BioLayout Express 3D and clustered based on relative expression profile in 
two separate comparisons—(a) 3 month Ppt1−/− spinal cord vs. 7 month Ppt1−/− spinal cord; and (b) or 3 month 
Ppt1−/− spinal cord vs. 3 month Ppt1−/− cortex. Algorithms in BioLayout Express 3D generate a visual network to 
represent each data set, in this study utilizing spatial proximity to represent the similarity in expression profile 
between  nodes25. It was therefore possible to isolate clusters of proteins grouped by similarity in terms of expres-
sion profiles over time. The resultant visual networks were utilized to distinguish expression clusters that fol-
lowed trends in expression that favored either group or both groups (3 vs. 7 month spinal cord analysis—altered 
only at 3 months, altered only at 7 months and similar/progressive alterations; 3 month cortex vs. 3 month spinal 
cord analysis—differential detection only in cortex, differential detection only in spinal cord and similar altera-
tions in both cortex and spinal cord at 3 months). These clusters were analyzed and input into Ingenuity Pathway 
Analysis (Ingenuity Systems).
14
Vol:.(1234567890)
Scientific RepoRtS |        (2020) 10:15157  | https://doi.org/10.1038/s41598-020-72075-7
www.nature.com/scientificreports/
Ingenuity pathway analysis (IPA). The IPA software (Ingenuity systems) contains a library of biological path-
ways published in the literature that are ranked by the significance of the association between the dataset and 
the canonical pathway. This significance is defined by two parameters: (a) the ratio of the number of proteins 
from the input dataset that are pertaining to a particular pathway divided by the total number of genes ascribed 
by the Ingenuity Knowledge Database to that canonical pathway and (b) a P value calculated using Fischer’s test 
that determines whether the probability of association between component proteins in the input dataset and the 
canonical pathway are due to chance. Prediction activation scores (z score) are a statistical measure of the match 
between an expected relationship direction and the observed protein expression within the input dataset. A 
positive z score indicates activation while a negative z score indicate  inhibitiony16,18,68. A 1.2 fold-change (20%) 
threshold filter was applied in IPA to the datasets for 3 month cortex, 3 month spinal cord and 7 month spinal 
cord (Ppt1−/− vs. wildtype respectively), analyzed and observed interactions were selected for this analysis.
Statistical analysis. All measurements for histological processing were performed blind to genotype. Statistical 
analysis for histological measurements of regional volumes, neuron counts, cell areas and thresholding image 
analysis as well as for QFWB analysis between two groups at a given time-point was calculated by multiple 
two-tailed, unpaired, parametric t test with Bonferroni-Dunn correction where p ≤ 0.05 was considered signifi-
cant using GraphPad Prism version 8.0.0 for MacOS (GraphPad Software, San Diego, CA, www.graph pad.com 
(2020)).
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